Sinonasal malignancies

• Verfasst von: Anschuetz, Lukas [VerfasserIn]
• Verfasst von: Hohenberger, Ralph [VerfasserIn]
• Verfasst von: Käcker, Christoph [VerfasserIn]
• Verfasst von: Elicin, Olgun [VerfasserIn]
• Verfasst von: Giger, Roland [VerfasserIn]
• Verfasst von: Caversaccio, Marco [VerfasserIn]
• Titel: Sinonasal malignancies
• Titelzusatz: histopathological entities, regional involvement and long-term outcome
• Verf.angabe: Lukas Anschuetz, Ralph Hohenberger, Christoph Kaecker, Olgun Elicin, Roland Giger and Marco Caversaccio
• E-Jahr: 2023
• Jahr: 28 April 2023
• Umfang: 9 S.
• Fussnoten: Gesehen am 28.06.2023
• Titel Quelle: Enthalten in: Journal of otolaryngology, head & neck surgery
• Ort Quelle: London : BioMed Central, 2008
• Jahr Quelle: 2023
• Band/Heft Quelle: 52(2023) vom: Apr., Artikel-ID 36, Seite 1-9
• ISSN Quelle: 1916-0216
• DOI: doi:10.1186/s40463-023-00627-8
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Mucosal melanoma
• Sach-SW: Nasal cancer
• Sach-SW: Rare cancer
• Sach-SW: Regional recurrence
• Sach-SW: Squamous cell carcinoma
• K10plus-PPN: 1851188851

Abstract

Background: To assess a large patient cohort with sinonasal malignancies focusing on regional involvement, recurrence and oncological outcome. Methods: Patients (n = 144) with malignant tumors of the nasal cavity and paranasal sinuses were treated at our tertiary referral center between 2008 and 2019. A chart review on patient and tumor characteristics, treatment and long-term outcome was performed. Results: Most frequent histological types were squamous cell carcinoma (SCC) (n = 74), adenocarcinoma (n = 24) and mucosal melanoma (n = 18). Primary therapy was surgery in 66% of patients (n = 95) of which 65.8% (n = 66) received adjuvant radiotherapy. Twenty patients (13.8%) were initially staged as cN + and in seven cases, pN + status was histopathologically confirmed. Fifty-six of 130 patients (43.1%) had a relapse after curative intended therapy, including nine loco-regional (6.9%) and seven isolated regional recurrences (5.4%). Twelve of these 16 patients with (loco-)regional recurrence had SCC. Adenoid cystic carcinoma (87.5%) and SCC (65.3%) showed the best long-term overall survival. Conclusions: Regional involvement and regional recurrence are scarce. Because of rarity and heterogeneity, evidence on therapeutic management is sparse resulting in the lack of clinical guidelines.